

NEW YORK CITY DISTRICT COUNCIL OF CARPENTERS BENEFIT FUNDS

UNION

TRUSTEES

Joseph A. Geiger
Co-Chairman

Paul Capurso
Michael P. Cavanaugh
Michael Rodin
John Sheehy

David Stewart
Executive Director

395 Hudson Street
New York, NY 10014
Telephone: (212) 366-7300

MANAGEMENT

TRUSTEES

David T. Meberg
Co-Chairman

John DeLollis
Kevin O'Callaghan
John O'Hare
Michael Salgo

IMPORTANT NOTICE

To: All Fund Participants

From: Board of Trustees of the New York City District Council of Carpenters Welfare Fund

Date: May 2020

This is an important notice concerning the health benefits provided by the New York City District Council of Carpenters Welfare Fund (the "Fund"). Please read this notice carefully, and keep it with your copy of the Fund's Summary Plan Description ("SPD").

Gene Therapy Exclusion

The Fund does not cover gene therapy. As such, the following paragraph is added to the SPD section entitled "Exclusions and Limitations:"

"Gene Therapy

Any and all charges for, or related to, gene therapy treatments, whether those therapies have received approval from the U.S. Food and Drug Administration (FDA) or not, or are considered experimental or investigational. For example, this exclusion applies to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies such as Kymriah and Yescarta, as well and Luxturna and Zolgensma, and to all new gene therapies that become available."

The following is added to the section of the SPD entitled "Glossary:"

"Gene Therapy: Gene therapy typically involves replacing a gene that causes a medical problem with one that does not, adding genes to help the body fight or treat disease, or inactivating genes that cause medical problems. The Fund does not cover any charges related to gene therapy, whether those therapies have received approval from the FDA or are considered experimental or investigational. Illustrative examples of gene therapy include Chimeric Antigen Receptor T-Cell (CAR-T) Therapies such as Kymriah and Yescarta, as well and Luxturna and Zolgensma, but new applications for gene therapies are submitted every year."

The following is added to the list of Expenses Not Covered in the Prescription Drug Benefit section of the SPD:

“No payment is made under this benefit for charges incurred for:

Charges related to gene therapy. The Fund does not cover any charges related to gene therapy, whether those therapies have received approval from the FDA or not or are considered experimental or investigational. See the Definitions section of the SPD for a definition of gene therapy.”

If you have questions, please contact the Fund Office at (212) 366-7373.

ERISA Information

Plan Sponsor: Board of Trustees of the New York City District Council of Carpenters Welfare Fund

Sponsor's EIN #: 13-5615576

Plan Number: 501

Plan Year: July 1